Loading...

XENE XENON PHARMACEUTICALS INC US FDA Inspections 8-K Filing

XNN

XN

XENON PHARMACEUTICALS INC

(XENE)

2026 8-K

Stock Options Increase

Annual Meeting Notice

Public Offering Announcement

Clinical Trial Results

Equity Offering Update

Financial Results Announced

Stock Option Plan

Financial Results Report

Management Change

Management Change

Annual Meeting Notice

Accounting Firm Change

Management Change

Management Change

Financial Results

Financial Results Announcement

Annual Meeting of Shareholders

Financial Results Announcement

Departure of Directors

Meeting Announcement

Financial Results Announcement

Public Offering

Clinical Trial Results

Clinical Trial Failure

Financial Results Announcement

Financial Results Announcement

Appointment of Directors

Annual Meeting of Shareholders

Financial Results Announcement

Compensation Plan Adoption

Annual Meeting Announcement

Financial Results Announcement

External Links:

On March 9, 2026, Xenon Pharmaceuticals Inc. announced topline data from its Phase 3 X-TOLE2 study of azetukalner for focal onset seizures. This filing includes accompanying investor presentation materials.

AI Assistant

XENON PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.